This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.63% per year. These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
by Zacks Equity Research
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
by Zacks Equity Research
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Travere (TVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook
by Zacks Equity Research
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.
HALO or FOLD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HALO vs. FOLD: Which Stock Is the Better Value Option?
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HALO vs. FOLD: Which Stock Is the Better Value Option?
by Zacks Equity Research
HALO vs. FOLD: Which Stock Is the Better Value Option?
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HALO vs. FOLD: Which Stock Is the Better Value Option?
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
by Zacks Equity Research
Puma Biotechnology beats third-quarter 2024 estimates for both the top and the bottom lines. The company updates its 2024 financial guidance. Stock rallies.
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
by Zacks Equity Research
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
by Zacks Equity Research
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
by Zacks Equity Research
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
by Zacks Equity Research
MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion and $3.5 billion for 2024.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
by Zacks Equity Research
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.